<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03477006</url>
  </required_header>
  <id_info>
    <org_study_id>R34HL135224</org_study_id>
    <secondary_id>R34HL135224</secondary_id>
    <nct_id>NCT03477006</nct_id>
  </id_info>
  <brief_title>Pragmatic Prehospital Group O Whole Blood Early Resuscitation Trial</brief_title>
  <acronym>PPOWER</acronym>
  <official_title>Pragmatic Prehospital Group O Whole Blood Early Resuscitation (PPOWER) Trial: A Prospective, Interventional,Randomized, 3 Year, Pilot Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jason Sperry</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite advances in trauma resuscitation, a paucity of therapeutic interventions are&#xD;
      available early enough to reduce the downstream morbidity and mortality attributable to&#xD;
      hemorrhage, shock and coagulopathy. Due to the time sensitive nature of the treatment of&#xD;
      hemorrhage, the ideal resuscitation intervention would entail use of a blood product&#xD;
      containing all essential hemostatic components, closest to time of injury, where prevention&#xD;
      or reversal of the devastating downstream consequences of shock and coagulopathy can occur.&#xD;
      This proposal will characterized the efficacy of whole blood resuscitation initiated in the&#xD;
      prehospital setting to patients in hemorrhagic shock which represents this ideal intervention&#xD;
      post-injury. These results will have great potential to dramatically change the way trauma&#xD;
      resuscitation occurs today.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Traumatic injury represents an incredible health care burden in the United States and&#xD;
      worldwide. Hemorrhage is estimated to be responsible for over 40% of all trauma-related&#xD;
      deaths. Ongoing traumatic blood loss is complicated by the well-known 'lethal triad' of&#xD;
      coagulopathy, hypothermia and acidosis which results in further unbridled hemorrhage.&#xD;
      Uncontrolled bleeding, resultant shock and organ dysfunction remain the leading causes of&#xD;
      early in-hospital mortality. Despite advances in trauma resuscitation, a paucity of&#xD;
      therapeutic interventions are available early enough to reduce the downstream morbidity and&#xD;
      mortality attributable to hemorrhage, shock and coagulopathy.&#xD;
&#xD;
      In-hospital resuscitation of traumatic hemorrhage has changed over the past decade. The&#xD;
      underlying principle of current resuscitation practice focuses on preventing or reversing the&#xD;
      effects of coagulopathy with the early use of a balanced component transfusion strategy&#xD;
      (1:1:1 - plasma: packed red blood cells: platelets). This reconstituted strategy has also&#xD;
      been coined 'whole blood-like' resuscitation despite being inferior compositionally to whole&#xD;
      blood. The use of whole blood was historically the gold standard for treating hemorrhagic&#xD;
      shock during World War I and II, prior to sweeping changes in blood banking practice. Whole&#xD;
      blood use continues today and is thought to provide the bleeding patient the identical&#xD;
      components they are losing with maximal resuscitative and hemostatic effects.&#xD;
&#xD;
      Recent military experiences continue to show the benefits of fresh whole blood resuscitation&#xD;
      demonstrating significant survival and hemostatic advantages. Whole blood has also been&#xD;
      postulated to improve microcirculatory hemodynamics, reduce the 'storage lesion' effect and&#xD;
      minimize donor exposure risks. A recent civilian study has also demonstrated benefit using&#xD;
      modified whole blood after arrival to the hospital where appropriate blood typing and cross&#xD;
      matching was performed prior to transfusion. Due to the time sensitive nature of the&#xD;
      treatment of hemorrhage, the ideal resuscitation intervention would entail use of a blood&#xD;
      product containing all essential hemostatic components, closest to time of injury, where&#xD;
      prevention or reversal of the devastating downstream consequences of shock and coagulopathy&#xD;
      can occur.&#xD;
&#xD;
      Initiation of whole blood resuscitation in the prehospital setting and continued through the&#xD;
      in-hospital phase of treatment to patients in hemorrhagic shock represents this ideal&#xD;
      intervention post-injury. Essential to the prehospital initiation of whole blood&#xD;
      resuscitation in the civilian population is need for it to be transfused without the need for&#xD;
      blood typing or cross matching. Of similar importance is the need for cold storage and&#xD;
      recycling of any unused whole blood product, allowing maximal utility of this precious&#xD;
      resource.&#xD;
&#xD;
      Based upon the belief that early whole blood resuscitation represents the most efficacious&#xD;
      hemostatic resuscitation product for the management of hemorrhage, the University of&#xD;
      Pittsburgh is currently utilizing cold stored, low titer, platelet replete-leukocyte reduced,&#xD;
      group O whole blood (LTLR-WB) for urgent release in the emergency department, without the&#xD;
      need for blood typing or cross matching, for patients in hemorrhagic shock. The hypothesis is&#xD;
      that the initiation of LTLR-WB resuscitation in the prehospital setting with continuation&#xD;
      through the in-hospital acute resuscitation phase of care will significantly reduce the&#xD;
      morbidity and mortality attributable to hemorrhagic shock post-injury as compared to standard&#xD;
      prehospital and in-hospital resuscitation practice. Thus, a large pragmatic clinical trial is&#xD;
      needed to definitively establish the efficacy and safety of whole blood resuscitation&#xD;
      initiated in the prehospital setting. Only a high quality clinical trial will provide the&#xD;
      essential evidence to justify and provide the impetus for the use of this precious blood&#xD;
      banking resource early post-injury. Because of the challenges associated with execution of&#xD;
      these types of large trials particularly in the prehospital setting, it is essential to&#xD;
      establish feasibility of this approach in a pilot study and provide experience to inform a&#xD;
      definitive large, multicenter whole blood trial. The University of Pittsburgh has a track&#xD;
      record of prehospital interventional trials post-injury and the clinical research&#xD;
      infrastructure to successfully execute the following this trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow enrollment, financial considerations and global pandemic&#xD;
  </why_stopped>
  <start_date type="Actual">November 20, 2018</start_date>
  <completion_date type="Actual">October 30, 2020</completion_date>
  <primary_completion_date type="Actual">October 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>28 Day All Cause Mortality</measure>
    <time_frame>28 days from admission</time_frame>
    <description>28 day all cause mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Multiple Organ Failure</measure>
    <time_frame>28 days from admission</time_frame>
    <description>multiple organ failure using the Denver post-injury MOF score which is a summed score and when the score is 4 or greater from 4 organ system scores, MOF is designated; 4 organ systems (pulmonary [0-3], renal [0-3], hepatic [0-3], cardiovascular [0-3])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 Hour Mortality</measure>
    <time_frame>24 hours from admission</time_frame>
    <description>24 hour mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Hemorrhagic Shock</condition>
  <arm_group>
    <arm_group_label>LTLR-WB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receiving 2 units of low titer, leucocyte reduced, platelet replete whole blood initiated in the prehospital setting during air medical transport and continued (up to 6 units of whole blood followed by standard component resuscitation) thru the early in-hospital phase of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Receiving standard prehospital air medical care and standard of care component (1:1:1) trauma resuscitation thru the early in-hospital phase of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Whole blood</intervention_name>
    <description>Low titer, group O, leukocyte reduced, platelet replete, cold stored whole blood</description>
    <arm_group_label>LTLR-WB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Injured patients being transport via an air medical service with hypotension (SBP =/&lt;&#xD;
        90mmHg with tachycardia &gt;108 OR SBP=/&lt;70 without the tachycardia requirement)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Age &lt; 18 or &gt; 89 years&#xD;
&#xD;
        Isolated fall from standing injury mechanism&#xD;
&#xD;
        Brain matter exposed or penetrating brain injury (GSW)&#xD;
&#xD;
        CPR &gt; 5 mins with out ROSC&#xD;
&#xD;
        Isolated burns without evidence of traumatic injury&#xD;
&#xD;
        Isolated Drowning or Hanging&#xD;
&#xD;
        No Intravenous or Intraosseous access&#xD;
&#xD;
        Known prisoner or known pregnancy&#xD;
&#xD;
        Referral Hospital Admission&#xD;
&#xD;
        Wearing No PPOWER bracelet&#xD;
&#xD;
        Objection to study voiced by subject or family at scene&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Sperry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 19, 2018</study_first_submitted>
  <study_first_submitted_qc>March 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2018</study_first_posted>
  <results_first_submitted>September 4, 2021</results_first_submitted>
  <results_first_submitted_qc>September 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 6, 2021</results_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Jason Sperry</investigator_full_name>
    <investigator_title>Professor of Surgery and Critical Care Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Hemorrhagic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 4, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT03477006/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>LTLR-WB</title>
          <description>Receiving 2 units of low titer, leucocyte reduced, platelet replete whole blood initiated in the prehospital setting during air medical transport and continued (up to 6 units of whole blood followed by standard component resuscitation) thru the early in-hospital phase of care&#xD;
Whole blood: Low titer, group O, leukocyte reduced, platelet replete, cold stored whole blood</description>
        </group>
        <group group_id="P2">
          <title>Standard Care</title>
          <description>Receiving standard prehospital air medical care and standard of care component (1:1:1) trauma resuscitation thru the early in-hospital phase of care</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LTLR-WB</title>
          <description>Receiving 2 units of low titer, leucocyte reduced, platelet replete whole blood initiated in the prehospital setting during air medical transport and continued (up to 6 units of whole blood followed by standard component resuscitation) thru the early in-hospital phase of care&#xD;
Whole blood: Low titer, group O, leukocyte reduced, platelet replete, cold stored whole blood</description>
        </group>
        <group group_id="B2">
          <title>Standard Care</title>
          <description>Receiving standard prehospital air medical care and standard of care component (1:1:1) trauma resuscitation thru the early in-hospital phase of care</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="46"/>
            <count group_id="B3" value="86"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" lower_limit="27" upper_limit="64"/>
                    <measurement group_id="B2" value="51" lower_limit="36" upper_limit="62"/>
                    <measurement group_id="B3" value="48.5" lower_limit="33" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>28 Day All Cause Mortality</title>
        <description>28 day all cause mortality</description>
        <time_frame>28 days from admission</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LTLR-WB</title>
            <description>Receiving 2 units of low titer, leucocyte reduced, platelet replete whole blood initiated in the prehospital setting during air medical transport and continued (up to 6 units of whole blood followed by standard component resuscitation) thru the early in-hospital phase of care&#xD;
Whole blood: Low titer, group O, leukocyte reduced, platelet replete, cold stored whole blood</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Receiving standard prehospital air medical care and standard of care component (1:1:1) trauma resuscitation thru the early in-hospital phase of care</description>
          </group>
        </group_list>
        <measure>
          <title>28 Day All Cause Mortality</title>
          <description>28 day all cause mortality</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.91</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Multiple Organ Failure</title>
        <description>multiple organ failure using the Denver post-injury MOF score which is a summed score and when the score is 4 or greater from 4 organ system scores, MOF is designated; 4 organ systems (pulmonary [0-3], renal [0-3], hepatic [0-3], cardiovascular [0-3])</description>
        <time_frame>28 days from admission</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LTLR-WB</title>
            <description>Receiving 2 units of low titer, leucocyte reduced, platelet replete whole blood initiated in the prehospital setting during air medical transport and continued (up to 6 units of whole blood followed by standard component resuscitation) thru the early in-hospital phase of care&#xD;
Whole blood: Low titer, group O, leukocyte reduced, platelet replete, cold stored whole blood</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Receiving standard prehospital air medical care and standard of care component (1:1:1) trauma resuscitation thru the early in-hospital phase of care</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Multiple Organ Failure</title>
          <description>multiple organ failure using the Denver post-injury MOF score which is a summed score and when the score is 4 or greater from 4 organ system scores, MOF is designated; 4 organ systems (pulmonary [0-3], renal [0-3], hepatic [0-3], cardiovascular [0-3])</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.23</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>24 Hour Mortality</title>
        <description>24 hour mortality</description>
        <time_frame>24 hours from admission</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LTLR-WB</title>
            <description>Receiving 2 units of low titer, leucocyte reduced, platelet replete whole blood initiated in the prehospital setting during air medical transport and continued (up to 6 units of whole blood followed by standard component resuscitation) thru the early in-hospital phase of care&#xD;
Whole blood: Low titer, group O, leukocyte reduced, platelet replete, cold stored whole blood</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Receiving standard prehospital air medical care and standard of care component (1:1:1) trauma resuscitation thru the early in-hospital phase of care</description>
          </group>
        </group_list>
        <measure>
          <title>24 Hour Mortality</title>
          <description>24 hour mortality</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.76</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During Hospital admission up to 28 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>LTLR-WB</title>
          <description>Receiving 2 units of low titer, leucocyte reduced, platelet replete whole blood initiated in the prehospital setting during air medical transport and continued (up to 6 units of whole blood followed by standard component resuscitation) thru the early in-hospital phase of care&#xD;
Whole blood: Low titer, group O, leukocyte reduced, platelet replete, cold stored whole blood</description>
        </group>
        <group group_id="E2">
          <title>Standard Care</title>
          <description>Receiving standard prehospital air medical care and standard of care component (1:1:1) trauma resuscitation thru the early in-hospital phase of care</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>DVT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal bleed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ARDS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>pulmonary embolus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hyponatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jason Sperry</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>4128028270</phone>
      <email>sperryjl@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

